MX342000B - Peptidos ect2 y vacunas que los incluyen. - Google Patents
Peptidos ect2 y vacunas que los incluyen.Info
- Publication number
- MX342000B MX342000B MX2012011385A MX2012011385A MX342000B MX 342000 B MX342000 B MX 342000B MX 2012011385 A MX2012011385 A MX 2012011385A MX 2012011385 A MX2012011385 A MX 2012011385A MX 342000 B MX342000 B MX 342000B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- peptides
- nucleic acids
- substances
- compositions
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 229960005486 vaccine Drugs 0.000 title 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 208000006990 cholangiocarcinoma Diseases 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000010174 renal carcinoma Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a péptidos aislados derivados de la SEC ID NO: 42 y sus fragmentos que se acoplan a un antígeno HLA e inducen a los linfocitos T citotóxicos (CTL) y que por ende pueden ser utilizados en el contexto de la inmunoterapia del cáncer, más particularmente en las vacunas anticancerosas. Los péptidos de la invención incluyen tanto las secuencias de aminoácidos citadas con anterioridad como sus versiones modificadas en las cuales uno, dos o varios aminoácidos son sustituidos, eliminados, insertados o añadidos, siempre que estas versiones modificadas conserven la necesaria capacidad de acoplamiento a HLA y/o de inducción de los CTL de las secuencias originales. Además se proporcionan ácidos nucleicos que codifican a cualquiera de los péptidos mencionados con anterioridad, al igual que agentes, sustancias y/o composiciones farmacéuticas que incluyen o incorporan cualquiera de los péptidos o ácidos nucleicos mencionados con anterioridad. Los peptidos, acidos nucleicos, agentes farmacéuticos, sustancias y composiciones de la presente invención encuentran particular utilidad en el tratamiento de los cánceres y tumores, lo que, por ejemplo, incluye el cáncer vesical, el cáncer de mama, el cáncer cervical, el carcinoma colangiocelular, la CML, el cáncer colorrectal, el cáncer esofágico, el NSCLC, el linfoma, el cáncer pancreático, el cáncer de próstata, el carcinoma renal y el SCLC.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32057710P | 2010-04-02 | 2010-04-02 | |
| PCT/JP2011/001909 WO2011122022A1 (en) | 2010-04-02 | 2011-03-30 | Ect2 peptides and vaccines including the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012011385A MX2012011385A (es) | 2013-12-16 |
| MX342000B true MX342000B (es) | 2016-09-09 |
Family
ID=44711777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012011385A MX342000B (es) | 2010-04-02 | 2011-03-30 | Peptidos ect2 y vacunas que los incluyen. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8951975B2 (es) |
| EP (1) | EP2553096B1 (es) |
| JP (1) | JP5816965B2 (es) |
| KR (1) | KR101863557B1 (es) |
| CN (1) | CN102939379B (es) |
| AR (1) | AR081065A1 (es) |
| AU (1) | AU2011233401B2 (es) |
| BR (1) | BR112012024997B1 (es) |
| CA (1) | CA2795318C (es) |
| CO (1) | CO6571869A2 (es) |
| DK (1) | DK2553096T3 (es) |
| EA (1) | EA027940B1 (es) |
| ES (1) | ES2655437T3 (es) |
| IL (1) | IL222057A (es) |
| MX (1) | MX342000B (es) |
| NZ (1) | NZ603379A (es) |
| SG (1) | SG184165A1 (es) |
| TW (2) | TWI538685B (es) |
| WO (1) | WO2011122022A1 (es) |
| ZA (1) | ZA201207342B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| MY198087A (en) | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0239102A3 (en) | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Process for the formation of human-human hybridoma |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| AU6632496A (en) | 1995-08-03 | 1997-03-05 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| WO1998004720A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| US7393663B2 (en) * | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
| US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| CA2425671A1 (en) * | 2000-10-12 | 2002-04-18 | Exelixis, Inc. | Human ect2 and methods of use |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7227007B2 (en) * | 2000-12-28 | 2007-06-05 | Asahi Kasei Pharma Corporation | NF-κB activating gene |
| WO2002072631A2 (en) | 2001-03-14 | 2002-09-19 | Dakocytomation Denmark A/S | Mhc molecule constructs and their usesfor diagnosis and therapy |
| WO2002078524A2 (en) | 2001-03-28 | 2002-10-10 | Zycos Inc. | Translational profiling |
| WO2002096943A1 (en) * | 2001-05-25 | 2002-12-05 | Asahi Kasei Kabushiki Kaisha | Stat6-activating genes |
| US20030092616A1 (en) | 2001-05-25 | 2003-05-15 | Akio Matsuda | STAT6 activation gene |
| JP2005506833A (ja) * | 2001-06-04 | 2005-03-10 | キュラジェン コーポレイション | 抗原性ポリペプチドに結合する新規抗体、抗原をコード化する核酸、および使用方法 |
| WO2002099062A2 (en) | 2001-06-04 | 2002-12-12 | Curagen Corporation | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| CA2399569A1 (en) | 2001-09-25 | 2003-03-25 | Yusuke Nakamura | Diagnostic markers and drug targets for treatment of cancer |
| GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2005019475A2 (en) | 2003-08-20 | 2005-03-03 | Oncotherapy Science, Inc. | Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc) |
| WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| JP5109131B2 (ja) | 2005-02-10 | 2012-12-26 | オンコセラピー・サイエンス株式会社 | 膀胱癌を診断する方法 |
| US8053183B2 (en) | 2005-07-27 | 2011-11-08 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
| CN101283106A (zh) | 2005-07-27 | 2008-10-08 | 肿瘤疗法科学股份有限公司 | 小细胞肺癌的诊断方法 |
| US8003770B2 (en) | 2005-09-13 | 2011-08-23 | Mie University | T-cell receptor and nucleic acid encoding the receptor |
| CN101432022A (zh) | 2006-02-28 | 2009-05-13 | 肿瘤疗法科学股份有限公司 | 利用抗-EphA4抗体效应物作用损伤细胞的方法 |
| CA2666559A1 (en) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
| CN101589058A (zh) | 2006-10-20 | 2009-11-25 | 株式会社未来创药研究所 | 包含抗hb-egf抗体作为活性成分的癌症治疗剂 |
| TWI610939B (zh) * | 2007-02-21 | 2018-01-11 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| EP2105511A1 (en) | 2008-03-28 | 2009-09-30 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung |
| EP2321410A4 (en) * | 2008-07-16 | 2011-09-14 | Oncotherapy Science Inc | ONCOGEN ECT2 AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG AND SOPHAGE CANCER |
| TW201008574A (en) * | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
-
2011
- 2011-03-23 TW TW100109936A patent/TWI538685B/zh not_active IP Right Cessation
- 2011-03-23 TW TW105112382A patent/TW201627003A/zh unknown
- 2011-03-30 EP EP11762265.4A patent/EP2553096B1/en active Active
- 2011-03-30 CA CA2795318A patent/CA2795318C/en active Active
- 2011-03-30 ES ES11762265.4T patent/ES2655437T3/es active Active
- 2011-03-30 US US13/638,272 patent/US8951975B2/en active Active
- 2011-03-30 CN CN201180027360.5A patent/CN102939379B/zh active Active
- 2011-03-30 KR KR1020127028426A patent/KR101863557B1/ko active IP Right Grant
- 2011-03-30 WO PCT/JP2011/001909 patent/WO2011122022A1/en active Application Filing
- 2011-03-30 SG SG2012069696A patent/SG184165A1/en unknown
- 2011-03-30 BR BR112012024997-5A patent/BR112012024997B1/pt not_active IP Right Cessation
- 2011-03-30 AU AU2011233401A patent/AU2011233401B2/en not_active Ceased
- 2011-03-30 EA EA201291004A patent/EA027940B1/ru not_active IP Right Cessation
- 2011-03-30 JP JP2012543839A patent/JP5816965B2/ja active Active
- 2011-03-30 DK DK11762265.4T patent/DK2553096T3/en active
- 2011-03-30 MX MX2012011385A patent/MX342000B/es active IP Right Grant
- 2011-03-30 NZ NZ603379A patent/NZ603379A/en not_active IP Right Cessation
- 2011-04-01 AR ARP110101103A patent/AR081065A1/es unknown
-
2012
- 2012-09-23 IL IL222057A patent/IL222057A/en active IP Right Grant
- 2012-10-01 ZA ZA2012/07342A patent/ZA201207342B/en unknown
- 2012-10-03 CO CO12173572A patent/CO6571869A2/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| SG184165A1 (en) | 2012-10-30 |
| BR112012024997A2 (pt) | 2017-05-23 |
| EP2553096A4 (en) | 2013-11-13 |
| IL222057A (en) | 2017-12-31 |
| US8951975B2 (en) | 2015-02-10 |
| EA201291004A1 (ru) | 2013-04-30 |
| TW201627003A (zh) | 2016-08-01 |
| JP2013523082A (ja) | 2013-06-17 |
| KR101863557B1 (ko) | 2018-06-01 |
| CO6571869A2 (es) | 2012-11-30 |
| MX2012011385A (es) | 2013-12-16 |
| AU2011233401B2 (en) | 2015-03-26 |
| NZ603379A (en) | 2014-09-26 |
| US20130095128A1 (en) | 2013-04-18 |
| BR112012024997B1 (pt) | 2022-03-22 |
| WO2011122022A1 (en) | 2011-10-06 |
| EA027940B1 (ru) | 2017-09-29 |
| AU2011233401A1 (en) | 2012-10-25 |
| DK2553096T3 (en) | 2018-01-15 |
| ZA201207342B (en) | 2013-06-26 |
| TWI538685B (zh) | 2016-06-21 |
| AR081065A1 (es) | 2012-06-06 |
| CN102939379B (zh) | 2016-08-03 |
| EP2553096B1 (en) | 2017-11-22 |
| KR20130033367A (ko) | 2013-04-03 |
| JP5816965B2 (ja) | 2015-11-18 |
| TW201138803A (en) | 2011-11-16 |
| CN102939379A (zh) | 2013-02-20 |
| CA2795318A1 (en) | 2011-10-06 |
| CA2795318C (en) | 2018-11-13 |
| EP2553096A1 (en) | 2013-02-06 |
| ES2655437T3 (es) | 2018-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005060A (es) | Novedosos peptidos y combinaciones de peptidos para usarse en la inmunoterapia contra el cancer de pulmon, incluido el cancer de pulmon no microcitico (nsclc) y otros canceres. | |
| CR20210233A (es) | NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419) | |
| CR20200431A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 1. 2018-74) | |
| EP3545965A3 (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
| PH12018500004A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | |
| MX2011008763A (es) | Peptidos foxm1 y vacunas que contienen los mismos. | |
| MX2012011668A (es) | Peptidos cdca5 y vacunas que incluyen los mismos. | |
| SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
| MX350220B (es) | Peptidos de mphosph1 y vacunas que incluyen los mismos. | |
| MX2013014489A (es) | Peptidos sema5b y vacunas que incluyen los mismos. | |
| MX355759B (es) | Peptidos topk y vacunas que incluyen los mismos. | |
| MX2012011385A (es) | Peptidos ect2 y vacunas que los incluyen. | |
| MX344579B (es) | Peptidos hjurp y vacunas que incluyen los mismos. | |
| MX2022005570A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer. | |
| MX2013006014A (es) | Peptidos tomm34 y vacunas que los incluyen. | |
| MX2011008917A (es) | Peptidos vangl1 y vacunas que incluyen los mismos. | |
| SG10201408245WA (en) | Tmem22 peptides and vaccines including the same | |
| MX2015007015A (es) | Peptidos sema5b y vacunas que contienen los mismos. | |
| EP2370454A4 (en) | PEPTIDES WITH EPITAOPE WDRPUH AND VACCINES INCLUDING THEM | |
| TH126648B (th) | Ect2 เปปไทด์ และ วัคซีนที่รวมถึงสิ่งเดียวกันนั้น | |
| TH126648A (th) | Ect2 เปปไทด์ และ วัคซีนที่รวมถึงสิ่งเดียวกันนั้น |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |